A Study to Assess the Safety and Efficacy of ZPL389 With TCS/TCI in Atopic Dermatitis Patients

NCT03948334 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

123

Enrollment

INDUSTRY

Sponsor class

Stopped Core terminated due to lack of efficacy

Conditions

Atopic Dermatitis

Interventions

DRUG: ZPL389 30mg
DRUG: ZPL389 50mg
DRUG: TCS and/or TCI

Sponsor

Novartis Pharmaceuticals